Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy

Phase 3

Completed

Conditions: Gastrointestinal Neoplasms
Chemotherapy-induced Nausea and Vomiting

Interventions: Drug: Aprepitant
Drug: Palonosetron
Drug: Placebo Oral Tablet
Drug: Dexamethasone

First Posted Date: 2018-09-17

Last Posted Date: 2023-02-08

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 248

Registration Number: NCT03674294

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM

Phase 2

Active, not recruiting

Conditions: Smouldering Myeloma

Interventions: Drug: Carfilzomib
Drug: Dexamethasone
Drug: Lenalidomide

First Posted Date: 2018-09-17

Last Posted Date: 2023-11-01

Lead Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland

Target Recruit Count: 58

Registration Number: NCT03673826

Locations: 🇮🇹
IT-Roma-SAPIENZA, Roma, Italy
🇳🇱
NL-Hoofddorp-SPAARNEGASTHUIS, Hoofddorp, Netherlands
🇨🇿
CZ-Brno-UHBRNO, Brno, Czechia

and more 13 locations

Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma

Phase 2

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Ixazomib
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Daratumumab

First Posted Date: 2018-09-13

Last Posted Date: 2020-07-30

Lead Sponsor: University Hospital, Toulouse

Target Recruit Count: 45

Registration Number: NCT03669445

Locations: 🇫🇷
CHU Bordeaux, Bordeaux, France
🇫🇷
CHU de Dijon, Dijon, France
🇫🇷
CHRU de Lille, Lille, France

and more 9 locations

Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin

Phase 2

Conditions: Chemotherapy-induced Nausea and Vomiting
Adverse Event
Cervical Cancer

Interventions: Drug: Akynzeo
Drug: Dexamethasone

First Posted Date: 2018-09-12

Last Posted Date: 2021-12-14

Lead Sponsor: Christina Ruhlmann

Target Recruit Count: 80

Registration Number: NCT03668639

Locations: 🇩🇰
Department of Oncology, Odense University Hospital, Odense, Denmark

Dexamethasone Blunts the Hypotensive Effect of Spinal Anesthesia in Geriatric Patients Undergoing Lower Limb Orthopedic Surgeries

Phase 4

Completed

Conditions: Hypotension

Interventions: Drug: Placebo
Drug: Dexamethasone phosphate

First Posted Date: 2018-09-10

Last Posted Date: 2023-07-21

Lead Sponsor: Ain Shams University

Target Recruit Count: 110

Registration Number: NCT03664037

Locations: 🇪🇬
Ibrahim Mamdouh Esmat, Heliopolis, Cairo, Egypt

Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Phase 1

Withdrawn

Conditions: Multiple Myeloma

Interventions: Drug: ABI-009
Drug: Pomalidomide
Drug: Dexamethasone

First Posted Date: 2018-09-05

Last Posted Date: 2019-08-14

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT03657420

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

Dexamethasone and Induction of Delivery

Phase 1

Completed

Conditions: Induction of Labor Affected Fetus / Newborn

Interventions: Drug: Distilled Water
Drug: Dexamethasone

First Posted Date: 2018-09-05

Last Posted Date: 2018-09-05

Lead Sponsor: samar sayed el sayed

Target Recruit Count: 102

Registration Number: NCT03658590

Locations: 🇪🇬
Ain Shams University, Cairo, Egypt

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Phase 3

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Biological: bb2121
Drug: Daratumumab
Drug: Pomalidomide
Drug: Dexamethasone
Drug: Bortezomib
Drug: Ixazomib
Drug: Lenalidomide
Drug: Carfilzomib
Drug: Elotuzumab

First Posted Date: 2018-08-29

Last Posted Date: 2022-12-15

Lead Sponsor: Celgene

Target Recruit Count: 381

Registration Number: NCT03651128

Locations: 🇺🇸
Local Institution - 145, Los Angeles, California, United States
🇺🇸
Local Institution - 122, Los Angeles, California, United States
🇺🇸
Local Institution - 131, Atlanta, Georgia, United States

and more 57 locations

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Phase 3

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: Daratumumab
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2018-08-29

Last Posted Date: 2025-01-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 395

Registration Number: NCT03652064

Locations: 🇵🇱
Centrum Onkologii Ziemi Lubelskiej im sw Jana z Dukli, Lublin, Poland
🇺🇸
Innovative Clinical Research Inc, Cerritos, California, United States
🇺🇸
Baptist MD Anderson, Jacksonville, Florida, United States

and more 111 locations

Intraoperative Dexamethasone and Its Effect on Hyperglycemia

Phase 4

Withdrawn

Conditions: Diabetes Mellitus

Interventions: Drug: Dexamethasone
Other: No dexamethasone

First Posted Date: 2018-08-24

Last Posted Date: 2021-01-22

Lead Sponsor: Ascension Health

Registration Number: NCT03646916

Locations: 🇺🇸
Genesys Regional Medical Center, Grand Blanc, Michigan, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy